Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

British journal of cancer - 5 Jan 2010

Murukesh N, Dive C, Jayson G C

Abstract excerpt

Vascular endothelial growth factor (VEGF) has been confirmed as an important therapeutic target in randomised clinical trials in multiple disease settings. However, the extent to which individual patients benefit from VEGF inhibitors is unclear. If we are to optimise the use of these drugs or develop combination regimens that build on this efficacy, it is critical to identify those patients who are likely to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Bevacizumab
Share to Cell Hypoxia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Contrast Media

Share to Drug Delivery Systems

Share to Patient Selection

Share to Positron-Emission Tomography

Share to Receptors, Vascular Endothelial Growth Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 20010945
DOI: 10.1038/sj.bjc.6605483
PMCID: PMC2813747

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.PMID 20010945Read ↗

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.Semantic proximity Read ↗

Biomarkers of Angiogenesis in Colorectal CancerSemantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

VEGF-A: a critical regulator of blood vessel growthSemantic proximity Read ↗

Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.Semantic proximity Read ↗

Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models.Semantic proximity Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review).Semantic proximity Read ↗

Correlation of Perfusion Parameters with Genes Related to Angiogenesis Regulation in Glioblastoma: A Feasibility StudySemantic proximity Read ↗

Vascular endothelial growth factors VEGF-B and VEGF-CSemantic proximity Read ↗

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.